<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593747</url>
  </required_header>
  <id_info>
    <org_study_id>18199</org_study_id>
    <secondary_id>2015-002720-12</secondary_id>
    <nct_id>NCT02593747</nct_id>
  </id_info>
  <brief_title>To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup</brief_title>
  <acronym>Bordeaux</acronym>
  <official_title>A Single-dose, Single-center, Randomized, Open-label, Two-way Crossover Study in Healthy Adults to Assess the Bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) Versus Claritin Peach Syrup 1mg/mL (ANNA Formula)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) versus
      Claritin Peach Syrup 1mg/mL (ANNA Formula)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: Area Under the Concentration Versus Time Curve From Zero to the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) of Loratadine in Plasma (AUC[0-tlast]) After Single Oral Dose of Loratadine</measure>
    <time_frame>0 hour (h) (pre-dose) to 72 h post-dose</time_frame>
    <description>Area under the concentration versus time curve from zero to the last data point greater than (&gt;) LLOQ (AUC[0-tlast]) after single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Loratadine in Plasma After Single Oral Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Maximum observed loratadine concentration in plasma, directly taken from analytical data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (tmax) in Plasma After Single Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Time to reach maximum loratadine concentration in plasma after its single oral dose, directly taken from analytical data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC) of Loratadine in Plasma After Single Dose</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Area under the concentration versus time curve from zero to infinity after single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) Associated With the Terminal Slope of Loratadine After Single Dose</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Half-life associated with the terminal slope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CL/F) of Loratadine Calculated After its Single Oral Administration</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Total body clearance of loratadine calculated after extravascular application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Area Under the Concentration Versus Time Curve (AUC) From the Last Calculated Data Point Greater Than Lower Limit of Quantification [LLOQ]) to Infinity (%AUC[tlast-∞]) After Single Oral Administration of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Percentage of AUC from the last calculated data point &gt; LLOQ to infinity was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) of Loratadine After Single Dose</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Apparent terminal rate constant, calculated from the slope of a log-linear regression of the unweighted data considering the last concentration-time points &gt; LLOQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Zero to 72 Hours (AUC[0-72]) of Lloratadine in Plasma After Single Oral Dose</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Area under the concentration versus time curve from zero to 72 h after single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Desloratadine in Plasma After Single Oral Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Maximum observed desloratadine concentration in plasma, directly taken from analytical data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (tmax) of Desloratadine in Plasma After Single Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Time to reach maximum drug concentration in the measured matrix, directly observed from the analytical data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Zero to the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) of Desoratadine in Plasma (AUC[0-tlast]) After Single Oral Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Area under the concentration versus time curve from zero to the last data point &gt; LLOQ (AUC[0-tlast]) after single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Zero to 72 Hours (AUC[0-72]) of Desloratadine in Plasma After Single Oral Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Area under the concentration versus time curve from zero to 72 h after single dose. AUC and residual area were not evaluated because the concentration at 72 h was quantifiable in the majority of profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Last Concentration Above the Lower Limit Of Quantitation (LLOQ) of Desloratadine, Directly Taken From Analytical Data (tlast)</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Time of last concentration above LLOQ, directly taken from analytical data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) Associated With the Terminal Slope of Desoratadine After Single Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Half-life associated with the terminal slope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Area Under the Concentration Versus Time Curve (AUC) from the Last Data Point Greater Than Lower Limit of Quantitation (LLOQ) to Infinity (%AUC[tlast-∞]) of Desoratadine After Single Oral Administration of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Percentage of area under the concentration versus time curve from zero to the last data point &gt; LLOQ in plasma (AUC[(0-tlast]) was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Rate Constant (λz) of Desoratadine After Single Dose of Loratadine</measure>
    <time_frame>0 h (pre-dose) to 72 h post-dose</time_frame>
    <description>Apparent terminal rate constant, calculated from the slope of a log-linear regression of the unweighted data considering the last concentration-time points &gt; LLOQ.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Histamine H1 Antagonists, Non-Sedating</condition>
  <arm_group>
    <arm_group_label>Loratadine oral solution/syrup then Claritin peach syrup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Claritin peach syrup then Loratadine oral solution/syrup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine oral solution</intervention_name>
    <description>Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.</description>
    <arm_group_label>Loratadine oral solution/syrup then Claritin peach syrup</arm_group_label>
    <arm_group_label>Claritin peach syrup then Loratadine oral solution/syrup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine (Claritin peach syrup)</intervention_name>
    <description>Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.</description>
    <arm_group_label>Loratadine oral solution/syrup then Claritin peach syrup</arm_group_label>
    <arm_group_label>Claritin peach syrup then Loratadine oral solution/syrup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult (men or women), age 18 to 55 years inclusive;

          -  Body mass index 18.5 to 30.0 kg/m*2 inclusive;

          -  Able to read and understand the written informed consent for study-related information
             and instruction;

          -  Able to comply with protocol requirements, including overnight stays, blood sample
             collections as defined in the protocol;

          -  Agree not to donate whole blood or components of blood (e.g. plasma, thrombocytes)
             starting from signing the informed consent form through 30 days after the last study
             procedure, except for the blood samples collected for this study;

          -  Female subjects of childbearing potential must be using a medically acceptable form of
             birth control for at least 1 month prior to screening (3 months on oral
             contraceptives), e.g., oral or patch contraceptives, intrauterine device, injectable
             contraceptive (e.g. Depo-Provera), or a double barrier and have a negative pregnancy
             test at Screening and prior to study drug administration on Day 0 of Dosing Periods 1
             and 2. Female subjects of non-childbearing potential must be amenorrheic for at least
             two years or had a hysterectomy and/or bilateral oophorectomy;

        Exclusion Criteria:

          -  Pre-existing diseases for which it can be assumed that the absorption, distribution,
             metabolism, elimination and effects of the study drugs will not be normal;

          -  Known hypersensitivity to any medication (active substances or excipients of the
             preparations) to be used in the study;

          -  Known galactose intolerance, lactase deficiency or glucose-galactose malabsorption

          -  Known severe allergies (e.g. allergies to more than 3 allergens, allergies affecting
             the lower respiratory tract - allergic asthma, allergies requiring therapy with
             corticosteroids);

          -  Use of, within 1 month before the first study drug administration, systemic or topical
             medicines or substances which might affect the study objectives, e.g

               -  any drug known to induce cytochrome P3A4/5 or P Glycoprotein (e.g. rifampin,
                  carbamazepine, St. John's wort);

               -  any drug known to inhibit cytochrome P3A4/5 or P Glycoprotein (e.g. erythromycin,
                  clarithromycin, chloramphenicol, ketoconazole);

               -  any drug known to induce cytochrome P2D6 (e.g. rifampin, dexamethasone);

               -  any drug known to inhibit cytochrome P2D6 (e.g. cimetidine, desipramine,
                  fluoxetine, metoclopramide);

          -  Positive urine pregnancy, urine drug test or Hepatitis B, hepatitis C or HIV tests;

          -  Clinically relevant findings in the physical examination, e.g., signs of bleeding
             diathesis, signs of heart failure, evidence of peripheral circulatory disturbances,
             and skin abnormalities;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neu-Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2015</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

